NewLink Genetics Corporation (NLNK)
-NasdaqGM 16.04 
0.50(3.22%) 4:00PM EDT
| Prev Close: | 15.54 |
|---|
| Open: | 15.14 |
|---|
| Bid: | N/A |
|---|
| Ask: | 17.00 x 300 |
|---|
| 1y Target Est: | 20.90 |
|---|
| Beta: | 0.486 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 15.07 - 16.17 |
|---|
| 52wk Range: | 10.60 - 18.00 |
|---|
| Volume: | 82,023 |
|---|
| Avg Vol (3m): | 149,210 |
|---|
| Market Cap: | 410.69M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.22 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NewLink Genetics to Be Added to NASDAQ Biotechnology IndexMarketwired(Thu, May 16)
- NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the ASCO 2013 Annual MeetingMarketwired(Thu, May 16)
- NEWLINK GENETICS CORP Files SEC form 8-K, Other EventsEDGAR Online(Thu, May 16)
- NEWLINK GENETICS CORP FinancialsEDGAR Online Financials(Wed, May 15)
- NEWLINK GENETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. oEDGAR Online(Tue, May 14)
- 3 Biotech Stocks Spiking With Big Volumeat TheStreet(Mon, May 13)
- NEWLINK GENETICS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- NewLink Genetics Corporation Reports First Quarter 2013 Financial ResultsMarketwired(Mon, May 6)
- NEWLINK GENETICS CORP Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Mon, May 6)
- Finding Innovative Drugs that are Genuinely Differentiated and Not an Incremental Improvement is the Key to Biotech Success, According to Expert Analyst Boris PeakerWall Street Transcript(Wed, May 1)
- NewLink Genetics: Looking To Join The Industry's Largest Moversat Seeking Alpha(Mon, Apr 29)
- NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare ConferencePR Newswire(Thu, Apr 25)
- NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual MeetingPR Newswire(Mon, Apr 8)
- NEWLINK GENETICS CORP Files SEC form 8-K, Other EventsEDGAR Online(Mon, Apr 8)
- NEWLINK GENETICS CORP Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, Apr 5)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 262.11 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.37 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.32 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
NewLink Genetics Corporation, a biopharmaceutical company, through its subsidiary, BioProtection Systems Corporation, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance cancer treatment options for patie...
View More